GW Pharmaceuticals plc: GW Pharmaceuticals to Report Q2 2014 Financial Results and Host Conference Call on 7 May, 2014

Tickers: GWPH

GW Pharmaceuticals to Report Q2 2014 Financial Results and Host Conference Call on 7 May, 2014

29  April  2014

London, UK, 29 April 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 May, 2014 its second quarter and half year financial results for the period ending 31 March, 2014. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type‑2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com .

Enquiries:

 GW Pharmaceuticals plc

(Today)  +44 20 3727 1000

 Justin Gover, CEO

+44 1980 557000

 Stephen Schultz, VP Investor Relations

+ 1 401 500 6570

 FTI Consulting

 Ben Atwell / Simon Conway / John Dineen (European media enquiries)

+ 44 20 3727 1000

 Robert Stanislaro (US media enquiries)

+1 212 850 5657

 Trout Group, LLC (US investor relations)

 Todd James / Chad Rubin

 +1 646 378 2900

distributed by

This noodl was issued by GW Pharmaceuticals plc and was initially posted at www.gwpharm.com. It was distributed, unedited and unaltered, by noodls on 2014-04-29 19:39:50 CET. The issuer is solely responsible for the accuracy of the information contained therein.